Impact of [18F]fluorodeoxyglucose positron emission tomography on surgical management of melanoma patients

British Journal of Surgery

Volumn 93, Issue 2, 2006, Pages 243-249

  Bastiaannet, E ^a   Oyen, W J G ^c   Meijer, S ^b   Hoekstra, O S ^b   Wobbes, T ^c   Jager, P L ^a   Hoekstra, H J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

CANCER STAGING; COLON POLYP; COLORECTAL CANCER; HUMAN; HYPOPHYSIS ADENOMA; MEDICAL RECORD; MELANOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECTUM POLYP; REVIEW; ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; EVALUATION; FEMALE; MALE; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; SCINTISCANNING; SKIN TUMOR; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MELANOMA; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 32944474087     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1002/bjs.5174     Document Type: Review

References (39)

1. 18F] fluoro-D-glucose whole body positron emission tomography for managing patients with melanoma: the referring physician's perspective. Mol Imaging Biol 2002; 4: 185-190.
2. Boyle P, Maisonneuve P, Dore JF. Epidemiology of malignant melanoma. Br Med Bull 1995; 51: 523-547.
3. Lee YT. Malignant melanoma: pattern of metastasis. CA Cancer J Clin 1980; 30: 137-142.
4. Abella-Columna E, Valk PE. Positron emission tomography imaging in melanoma and lymphoma. Semin Roentgenol 2002; 37: 129-139.
5. Monakhov NK, Neistadt EL, Shavlovskil MM, Shvartsman AL, Neifakh SA. Physicochemical properties and isoenzyme composition of hexokinase from normal and malignant human tissues. J Natl Cancer Inst 1978; 61: 27-34.
6. Weber MJ, Nakamura KD, Salter DW. Molecular events leading to enhanced glucose transport in Rous sarcoma virus-transformed cells. Fed Proc 1984; 43: 2246-2250.
7. Warburg O. On the origin of cancer cells. Science 1956; 123: 309-314.
8. Acland KM, Healy C, Calonje E, O'Doherty M, Nunan T, Page C et al. Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma. J Clin Oncol 2001; 19: 2674-2678.
9. Wagner JD, Schauwecker D, Davidson D, Coleman JJ III, Saxman S, Hutchins G et al. Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy. J Clin Oncol 1999; 17: 1508-1515.
10. Havenga K, Cobben DC, Oyen WJ, Nienhuijs S, Hoekstra HJ, Ruers TJ et al. Fluorodeoxyglucose-positron emission tomography and sentinel lymph node biopsy in staging primary cutaneous melanoma. Eur J Surg Oncol 2003; 29: 662-664.
11. Mijnhout GS, Hoekstra OS, van Lingen A, van Diest PJ, Ader HJ, Lammertsma AA et al. How morphometric analysis of metastatic load predicts the (un)usefulness of PET scanning: the case of lymph node staging in melanoma. J Clin Pathol 2003; 56: 283-286.
12. White RR, Tyler DS. Management of node-positive melanoma in the era of sentinel node biopsy. Surg Oncol 2000; 9: 119-125.
13. Fryback DG, Thornbury JR. The efficacy of diagnostic imaging. Med Decis Making 1991; 11: 88-94.
14. Thornbury JR, Eugene W. Caldwell Lecture. Clinical efficacy of diagnostic imaging: love it or leave it. AJR Am J Roentgenol 1994; 162: 1-8.
15. 18F-fluorodeoxyglucose positron emission tomography in recurrent melanoma. Nucl Med Commun 2002; 23: 475-481.
16. 18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986; 27: 235-238.
17. Brix G, Zaers J, Adam LE, Bellemann ME, Ostertag H, Trojan H et al. Performance evaluation of a whole-body PET scanner using the NEMA protocol. National Electrical Manufacturers Association. J Nucl Med 1997; 38: 1614-1623.
18. Dahlbom M, Hoffman EJ, Hoh CK, Schiepers C, Rosenqvist G, Hawkins RA et al. Whole-body positron emission tomography: Part I. Methods and performance characteristics. J Nucl Med 1992; 33: 1191-1199.
19. 18F-FDG PET on managing patients with colorectal cancer: the referring physician's perspective. J Nucl Med 2001; 42: 586-590.
20. 18F-FDG PET on staging and managing patients with breast cancer: the referring physician's perspective. J Nucl Med 2001; 42: 1334-1337.
21. Seltzer MA, Yap CS, Silverman DH, Meta J, Schiepers C, Phelps ME et al. The impact of PET on the management of lung cancer: the referring physician's perspective. J Nucl Med 2002; 43: 752-756.
22. Gulec SA, Faries MB, Lee CC, Kirgan D, Glass C, Morton DL et al. The role of fluorine-18 deoxyglucose positron emission tomography in the management of patients with metastatic melanoma: impact on surgical decision making. Clin Nucl Med 2003; 28: 961-965.
23. Damian DL, Fulham MJ, Thompson E, Thompson JF. Positron emission tomography in the detection and management of metastatic melanoma. Melanoma Res 1996; 6: 325-329.
24. Prichard RS, Hill AD, Skehan SJ, O'Higgins NJ. Positron emission tomography for staging and management of malignant melanoma. Br J Surg 2002; 89: 389-396.
25. 18F-fluorodeoxyglucose positron emission tomography in melanoma patients. Cancer 2001; 91: 1530-1542.
26. Steinert HC, Huch Boni RA, Buck A, Boni R, Berthold T, Marincek B et al. Malignant melanoma: staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1995; 195: 705-709.
27. 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer 1998; 82: 1664-1671.
28. Acland KM, O'Doherty MJ, Russell-Jones R. The value of positron emission tomography scanning in the detection of subclinical metastatic melanoma. J Am Acad Dermatol 2000; 42: 606-611.
29. Tyler DS, Onaitis M, Kherani A, Hata A, Nicholson E, Keogan M et al. Positron emission tomography scanning in malignant melanoma. Cancer 2000; 89: 1019-1025.
30. Valk PE, Segall GM, Johnson DL, Pounds TR, Tesar RD, Jadvar H et al. Cost-effectiveness of whole-body FDG PET imaging in metastatic melanoma. J Nucl Med 1997; 38: 90P (Abstract).
31. Jansen L, Nieweg OE, Peterse JL, Hoefnagel CA, Olmos RA, Kroon BBR et al. Reliability of sentinel lymph node biopsy for staging melanoma. Br J Surg 2000; 87: 484-489.
32. Jansen L, Koops HS, Nieweg OE, Doting MH, Kapteijn BA, Balm AJ et al. Sentinel node biopsy for melanoma in the head and neck region. Head Neck 2000; 22: 27-33.
33. Kumar R, Mavi A, Bural G, Alavi A. Fluorodeoxyglucose-PET in the management of malignant melanoma. Radiol Clin North Am 2005; 43: 23-33.
34. Finkelstein SE, Carrasquillo JA, Hoffman JM, Galen B, Choyke P, White DE et al. A prospective analysis of positron emission tomography and conventional imaging for detection of stage IV metastatic melanoma in patients undergoing metastasectomy. Ann Surg Oncol 2004; 11: 731-738.
35. Agress H Jr, Cooper BZ. Detection of clinically unexpected malignant and premalignant tumors with whole-body FDG PET: histopathologic comparison. Radiology 2004; 230: 417-422.
36. Balch CM. Cutaneous melanoma: prognosis and treatment results worldwide. Semin Surg Oncol 1992; 8: 400-414.
37. Weiss M, Loprinzi CL, Creagan ET, Dalton RJ, Novotny P, O'Fallon JR et al. Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. JAMA 1995; 274: 1703-1705.
38. Khansur T, Sanders J, Das SK. Evaluation of staging workup in malignant melanoma. Arch Surg 1989; 124: 847-849.
39. Swetter SM, Carroll LA, Johnson DL, Segall GM. Positron emission tomography is superior to computed tomography for metastatic detection in melanoma patients. Ann Surg Oncol 2002; 9: 646-653.